Search results for "030212 general & internal medicine"

showing 10 items of 6494 documents

Development of a database for the rapid and accurate routine identification of Achromobacter species by matrix-assisted laser desorption/ionization-t…

2019

International audience; Objectives: Achromobacter spp. are emerging pathogens in respiratory samples from cystic fibrosis patients. The current reference methods (nrdA-sequencing or multilocus sequence typing) can identify 18 species which are often misidentified by conventional techniques as A. xylosoxidans. A few studies have suggested that matrix-assisted laser desorption/ionization-time-of-flight mass spectrometry (MALDI-TOF/MS) provides accurate identification of the genus but not of species. The aims of this study were (a) to generate a database for MALDI-TOF/MS Bruker including the 18 species, (b) to evaluate the suitability of the database for routine laboratory identification, and …

0301 basic medicineMicrobiology (medical)MALDI-TOFAchromobacter speciesAchromobacterDatabases FactualRibonucleoside Diphosphate Reductase030106 microbiologyspecies identificationMatrix assisted laser desorption ionization time of flightAchromobacterBiologyMass spectrometrycomputer.software_genre03 medical and health sciences0302 clinical medicineHumans030212 general & internal medicineRespiratory samplesmass spectrometryDatabaseDiagnostic Tests RoutineGeneral Medicinebiology.organism_classification[SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/BacteriologynrdAIdentification (information)Matrix-assisted laser desorption/ionizationInfectious DiseasesSpectrometry Mass Matrix-Assisted Laser Desorption-IonizationMultilocus sequence typing[SDV.MP.BAC] Life Sciences [q-bio]/Microbiology and Parasitology/BacteriologyGram-Negative Bacterial InfectionscomputerSoftwareClinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
researchProduct

The unbalanced p53/SIRT1 axis may impact lymphocyte homeostasis in COVID-19 patients

2021

Abstract Background/objectives A dysregulated inflammatory profile plays an important role in coronavirus disease-2019 (COVID-19) pathogenesis. Moreover, the depletion of lymphocytes is typically associated with an unfavourable disease course. We studied the role and impact of p53 and deacetylase Sirtuin 1 (SIRT1) on lymph-monocyte homeostasis and their possible effect on T and B cell signalling. Methods Gene expression analysis and flow cytometry were performed on peripheral blood mononuclear cells (PBMC) of 35 COVID-19 patients and 10 healthy donors (HD). Inflammatory cytokines, the frequency of Annexin+ cells among CD3+ T cells and CD19+ B cell subsets were quantified. Results PBMC from …

0301 basic medicineMicrobiology (medical)Male030106 microbiologyInflammationInfectious and parasitic diseasesRC109-216CD19ArticleProinflammatory cytokineBLNK Inflammation03 medical and health sciences0302 clinical medicineSirtuin 1Lymphocyte homeostasismedicineHomeostasisHumans030212 general & internal medicineLymphocytesInterleukin-7 receptorB cellAgedInflammationBLNKbiologySirtuin 1SARS-CoV-2COVID-19p53/SIRT1General MedicineIL-7RMiddle Agedmedicine.anatomical_structureInfectious DiseasesSettore MED/38 - PEDIATRIA GENERALE E SPECIALISTICABLNK; COVID-19; IL-7R; inflammation; p53/SIRT1ImmunologyB-cell linkerbiology.proteinCytokinesFemalemedicine.symptomTumor Suppressor Protein p53
researchProduct

Dosing of caspofungin based on a pharmacokinetic/pharmacodynamic index for the treatment of invasive fungal infections in critically ill patients on …

2017

Abstract Introduction The study objective was to evaluate the efficacy of different dosages of caspofungin in the treatment of invasive candidiasis and aspergillosis, in relation to the probability of pharmacokinetic/pharmacodynamic (PK/PD) target attainment, using modelling and Monte Carlo simulations in critically ill adult patients on continuous haemodiafiltration. Methods Critically ill adult patients on continuous venovenous haemodiafiltration treated with caspofungin were analysed. A population PK model was developed. Four caspofungin dosing regimens were simulated: the licensed regimen, 70 mg/day, 100 mg/day or 200 mg/day. A PK/PD target was defined as the ratio between the area unde…

0301 basic medicineMicrobiology (medical)MaleAntifungal AgentsCandida parapsilosisCritical Illness030106 microbiologyPopulationCandida glabrataHemodiafiltrationMicrobial Sensitivity TestsPharmacologyAspergillosis03 medical and health scienceschemistry.chemical_compoundEchinocandinsLipopeptides0302 clinical medicinePharmacokineticsCaspofunginCandida albicansMedicineHumansPharmacology (medical)Candidiasis Invasive030212 general & internal medicineDosingeducationAgedAged 80 and overInvasive Pulmonary Aspergillosiseducation.field_of_studyMaintenance dosebusiness.industryCandidiasisGeneral MedicineMiddle Agedmedicine.diseaseRegimenInfectious DiseasesAspergilluschemistryPharmacodynamicsFemaleCaspofunginbusinessInternational journal of antimicrobial agents
researchProduct

Pertussis: Microbiology, Disease, Treatment, and Prevention

2016

SUMMARY Pertussis is a severe respiratory infection caused by Bordetella pertussis , and in 2008, pertussis was associated with an estimated 16 million cases and 195,000 deaths globally. Sizeable outbreaks of pertussis have been reported over the past 5 years, and disease reemergence has been the focus of international attention to develop a deeper understanding of pathogen virulence and genetic evolution of B. pertussis strains. During the past 20 years, the scientific community has recognized pertussis among adults as well as infants and children. Increased recognition that older children and adolescents are at risk for disease and may transmit B. pertussis to younger siblings has undersc…

0301 basic medicineMicrobiology (medical)MaleBordetella pertussismedicine.medical_specialtyEpidemiologyWhooping Cough030106 microbiologyReviewsDiseaseDisease Outbreaks03 medical and health sciences0302 clinical medicineImmunityEpidemiologymedicineHumans030212 general & internal medicineWhooping coughImmunity CellularGeneral Immunology and Microbiologybiologybusiness.industryVaccinationPublic Health Environmental and Occupational HealthOutbreakRespiratory infectionmedicine.diseasebiology.organism_classificationVaccinationInfectious DiseasesEarly DiagnosisImmunologyFemalebusiness
researchProduct

Immunogenicity and Safety of Primary and Booster Vaccinations of a Fully Liquid DTaP-IPV-HB-PRP-T Hexavalent Vaccine in Healthy Infants and Toddlers …

2018

To support a fully liquid, diphtheria (D)-tetanus (T)-acellular pertussis (aP)-inactivated poliovirus (IPV)-hepatitis B (HB)-Haemophilus influenzae b (PRP-T) vaccine in Europe using a 2, 3, 4 month primary series and a booster at 11-15 months of age. Phase III, randomized, observer-blind studies in Germany and the Czech Republic. Participants who had not received HB vaccine were randomized to a 2, 3, 4 month primary series of DTaP-IPV-HB-PRP-T (group 1; N = 266) or a reconstituted DTaP-HB-IPV//PRP-T comparator (group 2; N = 263) and a booster of the same vaccine. Pneumococcal vaccine (PCV13) and rotavirus vaccine were coadministered at 2, 3, 4 months, and the booster was coadministered with…

0301 basic medicineMicrobiology (medical)MalePediatricsmedicine.medical_specialty030106 microbiologyImmunization SecondaryBooster doseAntibodies ViralDiphtheria-Tetanus-acellular Pertussis Vaccines03 medical and health sciences0302 clinical medicineImmunogenicity VaccineSuspensionsGermanyTetanus ToxoidMedicineHumansHepatitis B Vaccines030212 general & internal medicineVaccines CombinedDiphtheria-Tetanus-acellular Pertussis VaccinesImmunization ScheduleCzech RepublicHaemophilus VaccinesBooster (rocketry)business.industryDiphtheriaImmunogenicityVaccinationInfant NewbornInfantmedicine.diseaseRotavirus vaccineAntibodies BacterialVaccinationPoliovirus Vaccine InactivatedInfectious DiseasesPneumococcal vaccinePediatrics Perinatology and Child HealthFemalebusinessThe Pediatric infectious disease journal
researchProduct

Neisseria gonorrhoeae antimicrobial resistance in Spain: a prospective multicentre study.

2021

Abstract Objectives Gonococcal infection is one of the most reported sexually transmitted infections and antimicrobial resistance in Neisseria gonorrhoeae (NG) is challenging for the treatment of this infection. This observational study aimed to describe antimicrobial resistance of NG and epidemiological data from patients with gonococcal infection in eight regions of Spain, for updating the local therapeutic guidelines. Methods MICs of penicillin, cefixime, ceftriaxone, azithromycin, ciprofloxacin, fosfomycin and gentamicin were determined by Etest for all NG isolates recovered from 1 April 2018 to 30 September 2019 from 10 hospitals in Spain. Resistance determinants were identified using …

0301 basic medicineMicrobiology (medical)Malemedicine.medical_specialty030106 microbiologyMicrobial Sensitivity TestsFosfomycinAzithromycinAzithromycinmedicine.disease_cause03 medical and health sciencesGonorrheaSexual and Gender Minorities0302 clinical medicineAntibiotic resistanceCiprofloxacinInternal medicineDrug Resistance BacterialmedicineHumansPharmacology (medical)030212 general & internal medicineProspective StudiesHomosexuality MaleEtestPharmacologybusiness.industryCeftriaxoneNeisseria gonorrhoeaeAnti-Bacterial AgentsPenicillinCiprofloxacinInfectious DiseasesSpainNeisseria gonorrhoeaebusinessCefiximemedicine.drugThe Journal of antimicrobial chemotherapy
researchProduct

Efficacy and safety of dalbavancin in the treatment of acute bacterial skin and skin structure infections (ABSSSIs) and other infections in a real-li…

2020

Objectives: We evaluated the efficacy and safety of dalbavancin in ABSSSI and ‘other sites’ infections’ (OTA). Methods: Observational study involving 11 Italian hospitals including patients that received ≥1 dose of dalbavancin in 2016–2019. The outcome was end-of-treatment efficacy and safety in ABSSSI and OTA in a real-life setting. Results: 206 patients enrolled (males 50%, median age 62 [IQR 50–76] years), 60.2% ABSSSI, 39.8% OTA. 69.7% ABSSSI vs 90.7% OTA (p = 0.003) and 46.3% ABSSSI vs 37.2% OTA (p = 0.786) received previous and concomitant antibiotics, respectively. 82.5% reached clinical cure. Eleven (5.4%) patients had non-serious adverse events (AE). OTA patients showed longer hosp…

0301 basic medicineMicrobiology (medical)Malemedicine.medical_specialtyGram-positive infection030106 microbiologyReal life settingMicrobiology03 medical and health sciences0302 clinical medicineVirologyInternal medicineAntibiotic therapymedicineantibiotic therapyHumansacute bacterial skin and skin structure infection030212 general & internal medicineAgedRetrospective Studiesbusiness.industryDalbavancinOff-Label UseSkin Diseases BacterialMiddle Agedacute bacterial skin and skin structure infectionsAnti-Bacterial Agentssecond-generation lipoglycopeptide antibioticsHospitalizationacute bacterial skin and skin structure infections; antibiotic therapy; dalbavancin; Gram-positive infections; second-generation lipoglycopeptide antibioticsInfectious DiseasesItalyAcute DiseaseSkin structureObservational studyFemalesecond-generation lipoglycopeptide antibiotics.TeicoplaninbusinessGram-positive infectionsdalbavancin
researchProduct

Efficacy of a coordinated strategy for containment of multidrug-resistant Gram-negative bacteria carriage in a Neonatal Intensive Care Unit in the co…

2021

AbstractBackgroundAntimicrobial resistance in neonatal intensive care unit (NICU) patients is a threat, due to the frequent use of antimicrobial treatment and invasive devices in fragile babies. Since 2014 an active surveillance program of multidrug-resistant Gram-negative bacteria (MDR-GNB) carriage has been in place in the five NICUs of Palermo, Italy. In 2017 an increase in the prevalence of MDR-GNB, and in particular of extended-spectrum β-lactamases-producingKlebsiella pneumoniae(ESBL-KP), was observed in “Civico” hospital NICU.AimTo assess the impact of a coordinated intervention strategy in achieving long-lasting reduction of MDR-GNB prevalence in the NICU.MethodsRectal swabs were ob…

0301 basic medicineMicrobiology (medical)Malemedicine.medical_specialtyNeonatal intensive care unit030106 microbiologyExtended spectrum β lactamases producing klebsiella pneumoniaeContext (language use)Drug resistanceMicrobial Sensitivity TestsAntimicrobial resistancelcsh:Infectious and parasitic diseases03 medical and health sciences0302 clinical medicineAntibiotic resistanceMedical microbiologyNeonatal intensive care unitInternal medicineDrug Resistance Multiple BacterialIntensive Care Units NeonatalGram-Negative BacteriamedicineHumansPharmacology (medical)lcsh:RC109-216030212 general & internal medicineNeonatal intensive care unit.Cross InfectionInfection ControlActive surveillance programbusiness.industryResearchPublic Health Environmental and Occupational HealthInfant NewbornAntimicrobialMulti-drug resistant gram-negative bacteriaElectrophoresis Gel Pulsed-FieldInfectious DiseasesCarriageItalyIntervention strategyCarrier StateFemaleSample collectionbusinessGram-Negative Bacterial Infections
researchProduct

Real-time polymerase chain reaction detection of Lichtheimia species in bandages associated with cutaneous mucormycosis in burn patients

2018

Summary Background Cutaneous mucormycoses, mainly due to Lichtheimia (Absidia), have occurred on several occasions in the Burn Unit of the University Hospital of Lille, France. Aim To investigate the potential vector role of non-sterile bandages used to hold in place sterile gauze used for wound dressing. Methods Mycological analysis by conventional culture, Mucorales real-time polymerase chain reaction (qPCR), and Lichtheimia species-specific qPCR were performed on eight crepe and six elasticized bandages that were sampled on two independent occasions in March 2014 and July 2016. Characteristics of the seven Lichtheimia mucormycoses which occurred in burn patients between November 2013 and…

0301 basic medicineMicrobiology (medical)MucoralesAdultMalemedicine.medical_specialtyLichtheimia corymbifera030106 microbiologyBurnReal-Time Polymerase Chain Reaction[ SDV.EE.SANT ] Life Sciences [q-bio]/Ecology environment/HealthHospitals UniversityCutaneous mucormycosis03 medical and health sciencesBandageMucorales qPCR0302 clinical medicineAbsidiaMedicineDermatomycosesHumansMucormycosis030212 general & internal medicineAged[SDV.EE.SANT]Life Sciences [q-bio]/Ecology environment/HealthCutaneous mucormycosisbiologybusiness.industryMucormycosisGeneral MedicineMiddle Agedbiology.organism_classificationmedicine.diseaseUniversity hospitalDermatologyBandages3. Good healthLichtheimia speciesInfectious DiseasesReal-time polymerase chain reactionMolecular Diagnostic TechniquesMucoralesFemaleFrancebusinessBurnsBandage
researchProduct

Recombinant GII.P16 genotype challenges RT-PCR-based typing in region A of norovirus genome

2021

Abstract Objectives In latest years GII.4[P16] and GII.2[P16] noroviruses have become predominant in some temporal/geographical settings. In parallel with the emergence of the GII.P16 polymerase type, norovirus surveillance activity in Italy experienced increasing difficulties in generating sequence data on the RNA polymerase genomic region A, using the widely adopted JV12A/JV13B primer set. Two sets of modified primers (Deg1 and Deg2) were tested in order to improve amplification and typing of the polymerase gene. Methods Amplification and typing performance of region A primers was assessed in RT-PCR on 452 GII norovirus positive samples obtained from 2194 stool samples collected in 2016–2…

0301 basic medicineMicrobiology (medical)Settore MED/07 - Microbiologia E Microbiologia ClinicaGenotype030106 microbiologymedicine.disease_cause03 medical and health scienceschemistry.chemical_compoundfluids and secretions0302 clinical medicineRNA polymeraseGenotypemedicineHumans030212 general & internal medicineTypingChildPolymerase GenePhylogenyPolymeraseCaliciviridae InfectionsbiologyReverse Transcriptase Polymerase Chain ReactionNorovirusvirus diseasesVirologyInfectious DiseasesReal-time polymerase chain reactionItalychemistryDegenerate primers GII.P16 Norovirus PolymeraseTypingNorovirusbiology.proteinPrimer (molecular biology)Journal of Infection
researchProduct